BACKGROUND: Both infarct size and microvascular obstruction (MO) assessed by cardiac magnetic resonance imaging (CMR) are known to be predictors for adverse clinical outcome after ST-elevation myocardial infarction (STEMI). We hypothesized that a ratio of MO and infarct size (MO/infarct size) might be an even stronger predictor for outcome after STEMI, which has not been investigated yet. METHODS: STEMI patients reperfused by primary angioplasty (n = 438) within 12 h after symptom onset underwent contrast-enhanced CMR at a median of 3 days (interquartile range [IQR] 2;4) after the index event. MO and infarct size were measured 15 min after intravenous gadolinium injection. Follow-up was conducted after 19 months (IQR 10;27). The primary end point was defined as a composite of death, non-fatal myocardial reinfarction and congestive heart failure (major adverse cardiac events [MACE]). RESULTS: The extent of MO was only weakly correlated with infarct size (r = 0.21, p < 0.001). In a first multivariate analysis including extent of MO, infarct size, ejection fraction, end-systolic and end-diastolic volume, the extent of MO was independently associated with MACE (hazard ratio [HR] 1.03, 95%CI 1.02–1.05, p < 0.001). In a second multivariate analysis including MO/infarct size on top of the extent of MO, infarct size, ejection fraction, end-systolic and end-diastolic volume, MO/infarct size was identified as the strongest independent predictor for MACE (HR 2.22 [95%CI 1.60–3.08, p < 0.001]). CONCLUSIONS: In contrast to infarct size, MO is associated with adverse clinical outcome after STEMI even after adjustment for other CMR parameters. However, MO/infarct size is a more powerful predictor for long-term outcome after STEMI than either parameter alone.
BACKGROUND: Both infarct size and microvascular obstruction (MO) assessed by cardiac magnetic resonance imaging (CMR) are known to be predictors for adverse clinical outcome after ST-elevation myocardial infarction (STEMI). We hypothesized that a ratio of MO and infarct size (MO/infarct size) might be an even stronger predictor for outcome after STEMI, which has not been investigated yet. METHODS: STEMI patients reperfused by primary angioplasty (n = 438) within 12 h after symptom onset underwent contrast-enhanced CMR at a median of 3 days (interquartile range [IQR] 2;4) after the index event. MO and infarct size were measured 15 min after intravenous gadolinium injection. Follow-up was conducted after 19 months (IQR 10;27). The primary end point was defined as a composite of death, non-fatal myocardial reinfarction and congestive heart failure (major adverse cardiac events [MACE]). RESULTS: The extent of MO was only weakly correlated with infarct size (r = 0.21, p < 0.001). In a first multivariate analysis including extent of MO, infarct size, ejection fraction, end-systolic and end-diastolic volume, the extent of MO was independently associated with MACE (hazard ratio [HR] 1.03, 95%CI 1.02–1.05, p < 0.001). In a second multivariate analysis including MO/infarct size on top of the extent of MO, infarct size, ejection fraction, end-systolic and end-diastolic volume, MO/infarct size was identified as the strongest independent predictor for MACE (HR 2.22 [95%CI 1.60–3.08, p < 0.001]). CONCLUSIONS: In contrast to infarct size, MO is associated with adverse clinical outcome after STEMI even after adjustment for other CMR parameters. However, MO/infarct size is a more powerful predictor for long-term outcome after STEMI than either parameter alone.
Authors: Mirja Neizel; Simon Futterer; Henning Steen; Evangelos Giannitsis; Lars Reinhardt; Dirk Lossnitzer; Stephanie Lehrke; Allan S Jaffe; Hugo A Katus Journal: Clin Res Cardiol Date: 2009-07-07 Impact factor: 5.460
Authors: R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: W J Rogers; C M Kramer; G Geskin; Y L Hu; T M Theobald; D A Vido; S Petruolo; N Reichek Journal: Circulation Date: 1999-02-16 Impact factor: 29.690
Authors: K C Wu; R J Kim; D A Bluemke; C E Rochitte; E A Zerhouni; L C Becker; J A Lima Journal: J Am Coll Cardiol Date: 1998-11-15 Impact factor: 24.094
Authors: Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs Journal: Circulation Date: 2004-08-03 Impact factor: 29.690
Authors: Aernout M Beek; Olga Bondarenko; Farshid Afsharzada; Albert C van Rossum Journal: J Cardiovasc Magn Reson Date: 2009-03-09 Impact factor: 5.364
Authors: Andreas Seitz; Kai C Wollert; Gerd P Meyer; Jochen Müller-Ehmsen; Carsten Tschöpe; Andreas E May; Klaus Empen; Emmanuel Chorianopoulos; Benedikta Ritter; Jens Pirr; Lubomir Arseniev; Hans-Gert Heuft; Arnold Ganser; Eed Abu-Zaid; Hugo A Katus; Stephan B Felix; Meinrad P Gawaz; Heinz-Peter Schultheiss; Dennis Ladage; Johann Bauersachs; Heiko Mahrholdt; Simon Greulich Journal: Clin Res Cardiol Date: 2019-08-10 Impact factor: 5.460
Authors: Oliver Husser; Jose V Monmeneu; Clara Bonanad; Cristina Gomez; Fabian Chaustre; Julio Nunez; Maria P Lopez-Lereu; Gema Minana; Juan Sanchis; Luis Mainar; Vicente Ruiz; Maria J Forteza; Isabel Trapero; David Moratal; Francisco J Chorro; Vicente Bodi Journal: Int J Cardiovasc Imaging Date: 2013-06-04 Impact factor: 2.357
Authors: Michael J Lipinski; Courtney M McVey; Jeffrey S Berger; Christopher M Kramer; Michael Salerno Journal: J Am Coll Cardiol Date: 2013-05-30 Impact factor: 24.094
Authors: Sebastian J Reinstadler; Martin Reindl; Hans-Josef Feistritzer; Gert Klug; Agnes Mayr; Markus Kofler; Alexander Minh-Duc Tu; Luc Huybrechts; Johannes Mair; Wolfgang-Michael Franz; Bernhard Metzler Journal: Wien Klin Wochenschr Date: 2015-10-06 Impact factor: 1.704